73 related articles for article (PubMed ID: 1305733)
1. [Clinical estimation of 1-alpha-hydroxycholecalciferol in treatment of patients with chronic renal failure].
Chodorowski Z; Rutkowski B; Wielgosz A; Chamienia A; Sulima-Gillow A; Manitius A
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1093-5. PubMed ID: 1305733
[TBL] [Abstract][Full Text] [Related]
2. 1-alpha-OH-cholecalciferol (1-alpha-OHD3) and low phosphate diet in predialysis chronic renal failure: effects on renal function and on secondary hyperparathyroidism.
Coen G; Messa F; Massimetti C; Mazzaferro S; Manganiello M; Donato G; Finistauri D; Giuliano G; Cinotti GA
Acta Vitaminol Enzymol; 1984; 6(2):129-35. PubMed ID: 6496255
[TBL] [Abstract][Full Text] [Related]
3. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
4. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
5. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
[TBL] [Abstract][Full Text] [Related]
6. [Studies on intestinal 47 Calcium absorption in healthy subjects and patients with chronic renal failure as well as on the significance of vitamin D 3 or 25-hydroxycholecalciferol therapy in renal osteopathy].
Hesch RD; Gerlach W; Henning HV; Emrich D; Scheler F; Kattermann R
Dtsch Med Wochenschr; 1972 Nov; 97(45):1735-8 passim. PubMed ID: 4343379
[No Abstract] [Full Text] [Related]
7. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
8. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
Reutter FW; Sieber R; Olah AJ; Dambacher MA
Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
[TBL] [Abstract][Full Text] [Related]
9. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
[TBL] [Abstract][Full Text] [Related]
10. [The effect of recombinant human growth hormone on urea and creatinine kinetics and selected dialysis adequacy parameters in children with end-stage renal failure treated with peritoneal dialysis].
Jedrzejowski A; Dyras P; Pańczyk-Tomaszewska M; Mizerska-Wasiak M; Roszkowska-Blaim M; Pietrzyk JA; Gałazka B
Pol Merkur Lekarski; 2002 Sep; 13(75):191-5. PubMed ID: 12474568
[TBL] [Abstract][Full Text] [Related]
11. [The effect of alphacalcidol on calcium and phosphate metabolism in patients treated with hemodialysis].
Veljković S; Raicević R; Cukaranović R; Ralenković S; Stojanović M; Kostić S; Djordjević V; Radenković M
Srp Arh Celok Lek; 1996; 124 Suppl 1():117-8. PubMed ID: 9102869
[TBL] [Abstract][Full Text] [Related]
12. Zinc metabolism in patients with chronic renal failure during treatment with 1.25-dihydroxycholecalciferol: a controlled therapeutic trial.
Kiilerich S; Christiansen C; Christensen MS; Naestoft J
Clin Nephrol; 1981 Jan; 15(1):23-7. PubMed ID: 7214749
[TBL] [Abstract][Full Text] [Related]
13. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
14. [Osteocalcin in chronic hemodialysis patients as an additional parameter in the diagnosis of advanced secondary hyperparathyroidism].
Motz W
Acta Med Austriaca; 1989; 16(1):8-12. PubMed ID: 2785325
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC
J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
[TBL] [Abstract][Full Text] [Related]
17. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
18. [Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a lower SCr level].
Nakayama M; Tanno Y; Otsuka Y; Takahashi H; Ikeda M; Katoh N; Yokoyama K; Yamamoto H; Tokutome G; Hosoya T
Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):530-6. PubMed ID: 12476589
[TBL] [Abstract][Full Text] [Related]
19. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.
Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH
Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943
[No Abstract] [Full Text] [Related]
20. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.
Rostaing L; Moreau-Gaudry X; Baron E; Cisterne JM; Monroziès-Bernadet P; Durand D
Clin Nephrol; 1997 Apr; 47(4):248-55. PubMed ID: 9128792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
